Antengene

IPO

Treat Patients Beyond Borders

Public · Shanghai, China · Founded 2017 · $238.0M raised

Headquarters
Shanghai
Employees
201–500
Founded
2017
Business Model
B2B
Total Funding
$238.0M
Last Round
$97.0M Series CJul 2020
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Antengene Corporation Limited (SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, including ADCs, bispecific antibodies, and T cell engager programs developed on the proprietary AnTenGager® platform. Lead commercial asset XPOVIO® (selinexor) is approved in 10 Asia Pacific markets.

Summary

Antengene is a Biotech company based in Shanghai, China, founded in 2017. It has raised $238.0M in total across 3 rounds, most recently a $97.0M Series C round in Jul 2020. Investors include Fidelity Management, Boyu Capital and FountainVest Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPONov 2020
$335.0M

Sign up to see all 4 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech, Oncology
Private EquityTotal funding$607.0MJan 2024
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Antengene on Indexed.vc
<a href="https://indexed.vc/companies/antengene"><img src="https://indexed.vc/api/badge/company/antengene" alt="Antengene on Indexed.vc" width="260" height="76" /></a>